| Followers | 236 |
| Posts | 15425 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Monday, May 19, 2014 10:03:39 PM
From a pr, marketing, advertising perspective only - I think a separate PR addressing each area of focus (breast to brain metastasis, colon, melanoma, and "other") would be a unique way of presenting the information - with each given it's due on its own - as opposed to lumping it all together into one. I think if they did it like this, the interest would start to really grow - both as a result of the novel approach this type of public relations campaign would be - as well as for the amazing results we all hope direct is capable of. People would start to sit up and pay attention - and wonder what case will next be revealed. I know I am wondering what the next case will be. And didn't Les in his email imply something like that? I can't remember and I don't have time to go hunt for the post.
I don't know if the company has to give exact data (percentages of necrosis, etc.) by ASCO - or ever - or if they can wait and give that more detailed information at ASCO.
I think if I were an oncologist, and I'd read these multiple pr's (that didn't have the exact details), I would definitely stop by the monster NWBO booth at ASCO to inquire about those exact percentages.
I understand that wouldn't be the way most bio company's pr's are done - but NWBO doesn't do things in the usual way (speaking out when AF puts out a hit piece, etc.). And they have a product that appears to perhaps be "killing" all types of cancer - not just one. Which is also different.
Anyhow, it's more a marketing curiosity now to me as to how they plan to address this - I think either way, it'll be an interesting two weeks.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
